By SPC News Staff
The FDA approved relugolix (Orgovyx, Myovant Sciences), the first oral androgen deprivation therapy for adults with advanced prostate cancer.
As the first oral drug in this class, relugolix may reduce or eliminate the need for some patients “to visit the clinic for treatments that require administration by a health care provider,” said Richard Pazdur, MD, the director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic